Document is current

Article History

Received: 7 August 2022

Accepted: 5 September 2022

First Online: 24 September 2022

Declarations

:

: R. Ariyasu reports honoraria from CHUGAI PHARMACEUTICAL CO., Bristol Myers Squib, ONO PHARMACEUTICAL CO., Astrazeneca, outside the submitted work, K. Uchibori reports payment for lectures from DAIICHI SANKYO COMPANY, CHUGAI PHARMACEUTICAL CO., Bristol Myers Squib, ONO PHARMACEUTICAL CO., Astrazeneca, Eli Lilly, Novartis, Thermo Fisher Scientific, Takeda Pharmaceutical Company outside the submitted work. His spouse is an employee of DAIICHI SANKYO. S.Kitazono reports honoraria from Chugai Pharmaceutical Co, Ltd . AstraZeneca, Ono Pharmaceutical, Pfizer, Bristol-Myers Squibb and Merck Sharp & Dohme Corp outside the submitted work. N. Yanagitani reports honoraria from CHUGAI PHARMACEUTICAL CO., Bristol Myers Squib, ONO PHARMACEUTICAL CO., Astrazeneca, Eli Lilly, Takeda Pharmaceutical Company, Pfizer, Bayer Yakuhin, Ltd outside the submitted work. M. Nishio reports grants and personal fees from Ono Pharmaceutical, Bristol Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, MSD, Boehringer-Ingelheim, Novartis, Merck Biopharma, Daiichi Sankyo, Takeda Pharmaceutical Company Limited, personal fees from TEIJIN PHARMA LIMITED., AbbVie, outside the submitted work. The remaining authors have not conflicts of interest to declare.

: All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the Clinical Research Ethics Committee of Cancer Institute Hospital of JFCR.

: The ethics review board of Cancer Institute Hospital of JFCR approved the present study and permitted the use of the opt-out method in lieu of written informed consent.

: R. Ariyasu reports honoraria from CHUGAI PHARMACEUTICAL CO., Bristol Myers Squib, ONO PHARMACEUTICAL CO., Astrazeneca, outside the submitted work, K. Uchibori reports payment for lectures from DAIICHI SANKYO COMPANY, CHUGAI PHARMACEUTICAL CO., Bristol Myers Squib, ONO PHARMACEUTICAL CO., Astrazeneca, Eli Lilly, Novartis, Thermo Fisher Scientific, Takeda Pharmaceutical Company outside the submitted work. His spouse is an employee of DAIICHI SANKYO. S.Kitazono reports honoraria from Chugai Pharmaceutical Co, Ltd. AstraZeneca, Ono Pharmaceutical, Pfizer, Bristol-Myers Squibb and Merck Sharp & Dohme Corp outside the submitted work. N. Yanagitani reports honoraria from CHUGAI PHARMACEUTICAL CO., Bristol Myers Squib, ONO PHARMACEUTICAL CO., Astrazeneca, Eli Lilly, Takeda Pharmaceutical Company, Pfizer, Bayer Yakuhin, Ltd outside the submitted work. M. Nishio reports grants and personal fees from Ono Pharmaceutical, Bristol Myers Squibb, Pfizer, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, MSD, Boehringer-Ingelheim, Novartis, Merck Biopharma, Daiichi Sankyo, Takeda Pharmaceutical Company Limited, personal fees from TEIJIN PHARMA LIMITED., AbbVie, outside the submitted work. The remaining authors have not conflicts of interest to declare.